Ambulatory Hemodynamic Monitoring Reduces Heart Failure Hospitalizations in “Real-World” Clinical Practice

Akshay S. Desai, Arvind Bhimaraj, Rupinder Bharmi, Rita Jermyn, Kunjan Bhatt, David Shavelle, Margaret May Redfield, Robert Hull, Jamie Pelzel, Kevin Davis, Nirav Dalal, Philip B. Adamson, J. Thomas Heywood

Research output: Contribution to journalArticle

49 Scopus citations

Abstract

Background In the CHAMPION (CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in New York Heart Association [NYHA] Functional Class III Heart Failure Patients) trial, heart failure hospitalization (HFH) rates were lower in patients managed with guidance from an implantable pulmonary artery pressure sensor compared with usual care. Objectives This study examined the effectiveness of ambulatory hemodynamic monitoring in reducing HFH outside of the clinical trial setting. Methods We conducted a retrospective cohort study using U.S. Medicare claims data from patients undergoing pulmonary artery pressure sensor implantation between June 1, 2014, and December 31, 2015. Rates of HFH during pre-defined periods before and after implantation were compared using the Andersen-Gill extension to the Cox proportional hazards model while accounting for the competing risk of death, ventricular assist device implantation, or cardiac transplantation. Comprehensive heart failure (HF)–related costs were compared over the same periods. Results Among 1,114 patients receiving implants, there were 1,020 HFHs in the 6 months before, compared with 381 HFHs, 139 deaths, and 17 ventricular assist device implantations and/or transplants in the 6 months after implantation (hazard ratio [HR]: 0.55; 95% confidence interval [CI]: 0.49 to 0.61; p < 0.001). This lower rate of HFH was associated with a 6-month comprehensive HF cost reduction of $7,433 per patient (IQR: $7,000 to $7,884), and was robust in analyses restricted to 6-month survivors. Similar reductions in HFH and costs were noted in the subset of 480 patients with complete data available for 12 months before and after implantation (HR: 0.66; 95% CI: 0.57 to 0.76; p < 0.001). Conclusions As in clinical trials, use of ambulatory hemodynamic monitoring in clinical practice is associated with lower HFH and comprehensive HF costs. These benefits are sustained to 1 year and support the “real-world” effectiveness of this approach to HF management.

Original languageEnglish (US)
Pages (from-to)2357-2365
Number of pages9
JournalJournal of the American College of Cardiology
Volume69
Issue number19
DOIs
StatePublished - May 16 2017

    Fingerprint

Keywords

  • CardioMEMS
  • clinical effectiveness
  • implantable hemodynamic monitor

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Desai, A. S., Bhimaraj, A., Bharmi, R., Jermyn, R., Bhatt, K., Shavelle, D., Redfield, M. M., Hull, R., Pelzel, J., Davis, K., Dalal, N., Adamson, P. B., & Heywood, J. T. (2017). Ambulatory Hemodynamic Monitoring Reduces Heart Failure Hospitalizations in “Real-World” Clinical Practice. Journal of the American College of Cardiology, 69(19), 2357-2365. https://doi.org/10.1016/j.jacc.2017.03.009